Literature DB >> 21864238

Phosphine-gold(I) compounds as anticancer agents: general description and mechanisms of action.

João Carlos Lima1, Laura Rodriguez.   

Abstract

Gold complexes have been explored as metallodrugs with great potential applications as antitumoral agents. In particular, gold-phosphine derivatives seemed quite promising since the use of the antiarthritic auranofin drug (thiolate-Au-PEt3 complex) presented also biological activity against different cancer cells. So, different auranofin analogues have been explored within this context and for this reason, the main number of phosphine-gold complexes developed with this goal contain thiolate ligands. Other complexes have been also studied such as tetrahedral bis(phosphine)gold(I) and phosphine-gold-halides. Very recently, phosphine-gold-alkynyl complexes have also shown very interesting biological activities although few reports are published related to them. Their mechanism of action seems to be clearly different that the used by platinum drugs (DNA intercalating processes) and recent studies point to be related to the inhibition of Trx reductase. Cellular uptake and biodistribution studies are well reported in the original works but the use of luminescence techniques is relatively less explored. For this, the use of these techniques is also specifically reported in this review.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21864238     DOI: 10.2174/187152011797927670

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  9 in total

1.  Revisiting the anticancer properties of phosphane(9-ribosylpurine-6-thiolato)gold(I) complexes and their 9H-purine precursors.

Authors:  Luisa Kober; Sebastian W Schleser; Sofia I Bär; Rainer Schobert
Journal:  J Biol Inorg Chem       Date:  2022-10-16       Impact factor: 3.862

Review 2.  Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics.

Authors:  Maria Grazia Ferraro; Marialuisa Piccolo; Gabriella Misso; Rita Santamaria; Carlo Irace
Journal:  Pharmaceutics       Date:  2022-04-28       Impact factor: 6.525

3.  Effect of 2-chloro-substitution of adenine moiety in mixed-ligand gold(I) triphenylphosphine complexes on anti-inflammatory activity: the discrepancy between the in vivo and in vitro models.

Authors:  Jan Hošek; Ján Vančo; Pavel Štarha; Lenka Paráková; Zdeněk Trávníček
Journal:  PLoS One       Date:  2013-11-27       Impact factor: 3.240

4.  Gold-containing compound BDG-I inhibits the growth of A549 lung cancer cells through the deregulation of miRNA expression.

Authors:  Ali Alhoshani; A Alrashdi; Khaled Alhosaini; Fawaz E Alanazi; Nehad M Alajez; Muhammad Altaf; Anvarhusein A Isab; Hesham M Korashy
Journal:  Saudi Pharm J       Date:  2018-06-06       Impact factor: 4.330

5.  Antiproliferative activity exerted by tricyclohexylphosphanegold(I) n-mercaptobenzoate against MCF-7 and A2780 cell lines: the role of p53 signaling pathways.

Authors:  Kok Pian Ang; Pit Foong Chan; Roslida Abd Hamid
Journal:  Biometals       Date:  2020-11-16       Impact factor: 2.949

6.  Cancer cell-selective modulation of mitochondrial respiration and metabolism by potent organogold(iii) dithiocarbamates.

Authors:  Randall T Mertens; Sean Parkin; Samuel G Awuah
Journal:  Chem Sci       Date:  2020-09-18       Impact factor: 9.825

Review 7.  Gold-Based Medicine: A Paradigm Shift in Anti-Cancer Therapy?

Authors:  Chien Ing Yeo; Kah Kooi Ooi; Edward R T Tiekink
Journal:  Molecules       Date:  2018-06-11       Impact factor: 4.411

8.  Synthesis and Biological Evaluation of Homogeneous Thiol-Linked NHC*-Au-Albumin and -Trastuzumab Bioconjugates.

Authors:  Maria J Matos; Carlos Labão-Almeida; Claire Sayers; Oyinlola Dada; Matthias Tacke; Gonçalo J L Bernardes
Journal:  Chemistry       Date:  2018-05-22       Impact factor: 5.236

Review 9.  Computational Studies of Au(I) and Au(III) Anticancer MetalLodrugs: A Survey.

Authors:  Iogann Tolbatov; Alessandro Marrone; Cecilia Coletti; Nazzareno Re
Journal:  Molecules       Date:  2021-12-15       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.